Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer
NCT ID: NCT07009600
Last Updated: 2025-06-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
124 participants
OBSERVATIONAL
2010-01-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Conversion Surgery in Stage IV or Unresectable Gastric Cancer
NCT03366961
Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer
NCT06630130
Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC
NCT04168931
Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer
NCT02901301
First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
NCT06727981
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
immune check point inhibitors (PD-1 inhibitors), target therapy (trastuzumab)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients who underwent emergent surgery due to cancer perforation
* Patients with missing medical records or information
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sung Eun Oh
Clinical assistant professor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SMC 2025-03-046-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.